Skip to main content

Health Canada Authorizes CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B

CSL’s HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis

Material Transfers

Our Focus on Rare Serious Diseases

Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.

See How We're Leading the Way